Elena finds hope in new treatment for severe atopic eczema after years of suffering in Norway

At just 1.5 years old, Elena Vist, now 6, began to show classic signs of atopic eczema: dry skin, rashes, and when temperatures dropped, she would need to wear wool garments that exacerbated her condition. Initially deemed not severe, her eczema grew increasingly problematic, afflicting her for four years with a weeping rash that spread across her face, leading to crusted sores infected with staphylococci.

Elena required food to be administered in tiny pieces, and fluoride tablets replaced her dental care routine, ultimately leading to the extraction of four of her teeth.

Every winter, her condition worsened, with a routine development of a small red spot on her nose that would subsequently spread. Her mother, Monica, sought help from numerous doctors and skin specialists, desperately trying various ointments, but nothing proved effective.

A turning point came when they consulted a new general practitioner who recognized the severity of Elena’s situation after four years of suffering. This physician facilitated her referral to the Levanger hospital, where staff were shocked to learn how long the family had endured Elena’s condition.

Atopic eczema affects about 70% of cases in children under five. Most patients experience chronic symptoms of dry, itchy skin. However, after four difficult years, Elena found hope with a new medication discovered in 2023. This biologic treatment, suitable for children as young as six months, significantly transformed her life.

Monica is grateful for the breakthrough and hopes others in similar situations can obtain quicker assistance. Today, Elena can enjoy strawberries and participate in activities without embarrassment or limitations, marking a notable improvement in her quality of life.